TM-233

• Description :

  TM-233 is an inhibitor of the JAK/STAT and NF-κB signaling pathways, exhibiting significant antitumor activity. TM-233 reduces the expression of the anti-apoptotic protein Mcl-1 by inhibiting the phosphorylation of JAK2 and STAT3, and regulates its transcription by directly binding to the Mcl-1 gene promoter. Additionally, TM-233 prevents the translocation of NF-κB from the cytoplasm to the nucleus by inhibiting its DNA-binding activity, thereby reducing nuclear NF-κB expression. TM-233 shows potential in overcoming Bortezomib (HY-10227) resistance and can be applied in research related to multiple myeloma[1].

• UNSPSC :

  12352005

• Target :

  Bcl-2 Family; JAK; NF-κB; STAT

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Epigenetics; JAK/STAT Signaling; NF-κB; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/tm-233.html

• Smiles :

  CC(OC(C1=CC=C(C=C1)OC(C)=O)C2=C3C=CC=CC3=CC4=CC=CC=C24)=O

• Molecular Formula :

  C25H20O4

• Molecular Weight :

  384.42

• References & Citations :

  [1]Sagawa M, et al. TM-233 Exerts Anti-Myeloma Activity and Overcomes Bortezomib-Resistance In Human Multiple Myeloma Cells By Targeting NF-κB and JAK/STAT Dual-Signaling Pathways[J]. Blood, 2013, 122 (21) : 4427.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  JAK2; Mcl-1; STAT3

• CAS Number :

  [1103745-28-3]